A
Avinesh Pillai
Researcher at University of Auckland
Publications - 44
Citations - 5137
Avinesh Pillai is an academic researcher from University of Auckland. The author has contributed to research in topics: Randomized controlled trial & Type 2 diabetes. The author has an hindex of 16, co-authored 39 publications receiving 4564 citations. Previous affiliations of Avinesh Pillai include National Health and Medical Research Council & University of Sydney.
Papers
More filters
Journal ArticleDOI
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Anthony C Keech,R. J. Simes,Philip J. Barter,James D. Best,Russell S. Scott,Marja-Riitta Taskinen,Peta M. Forder,Avinesh Pillai,Tamara M. Davis,Paul Glasziou,Paul L. Drury,Y A Kesäniemi,David R. Sullivan,D Hunt,Peter G. Colman,Michael C d'Emden,Malcolm J. Whiting,Christian Ehnholm,Markku Laakso +18 more
TL;DR: Fenofibrate did not significantly reduce the risk of the primary outcome of coronary events, but it did reduce total cardiovascular events, mainly due to fewer non-fatal myocardial infarctions and revascularisations.
Journal ArticleDOI
Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes
Toshiharu Ninomiya,Vlado Perkovic,Bastiaan E. de Galan,Bastiaan E. de Galan,Sophia Zoungas,Avinesh Pillai,Meg Jardine,Anushka Patel,Alan Cass,Bruce Neal,Neil R Poulter,Carl-Eric Mogensen,Mark E. Cooper,Michel Marre,Bryan Williams,Pavel Hamet,Giuseppe Mancia,Mark Woodward,Mark Woodward,Stephen MacMahon,John Chalmers +20 more
TL;DR: In this article, the effects of albuminuria and reduced estimated GFR (eGFR) on the risk for cardiovascular and renal events among individuals with type 2 diabetes were investigated. But, there was no evidence of an interaction between the effect of higher eGFR and lower UACR.
Journal ArticleDOI
Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes
Bastiaan E. de Galan,Bastiaan E. de Galan,Vlado Perkovic,Toshiharu Ninomiya,Avinesh Pillai,Anushka Patel,Alan Cass,Bruce Neal,Neil R Poulter,Stephen B. Harrap,Carl Erik Mogensen,Mark E. Cooper,Michel Marre,Bryan Williams,Pavel Hamet,Giuseppe Mancia,Mark Woodward,Paul Glasziou,Diederick E. Grobbee,Stephen MacMahon,John Chalmers +20 more
TL;DR: BP-lowering treatment with perindopril-indapamide administered routinely to individuals with type 2 diabetes provides important renoprotection, even among those with initial BP <120/70 mmHg, and a BP threshold below which renal benefit is lost is not identified.
Journal ArticleDOI
Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study.
Xin Du,Toshiharu Ninomiya,Bastiaan E. de Galan,Bastiaan E. de Galan,Edward Abadir,John Chalmers,Avinesh Pillai,Mark Woodward,Mark Woodward,Mark E. Cooper,Stephen B. Harrap,Pavel Hamet,Neil R Poulter,Gregory Y.H. Lip,Anushka Patel +14 more
TL;DR: Atrial fibrillation is relatively common in type 1 diabetes and is associated with substantially increased risks of death and cardiovascular events in patients with type 2 diabetes, and this arrhythmia identifies individuals who are likely to obtain greater absolute benefits from blood pressure-lowering treatment.
Journal ArticleDOI
Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial
B.E. de Galan,Sophia Zoungas,Sophia Zoungas,John Chalmers,Craig S. Anderson,Carole Dufouil,Carole Dufouil,Avinesh Pillai,M. E. Cooper,Diederik E. Grobbee,Maree L. Hackett,Pavel Hamet,Simon Heller,Liu Lisheng,Stephen MacMahon,Giuseppe Mancia,Bruce Neal,C. Y. Pan,Anushka Patel,Neil R Poulter,F. Travert,Mark Woodward,Mark Woodward +22 more
TL;DR: Cognitive dysfunction is an independent predictor of clinical outcomes in patients with type 2 diabetes, but does not modify the effects of BP lowering or glucose control on the risks of major cardiovascular events.